CYTK - サイトキネティクス (Cytokinetics Incorporated) サイトキネティクス

 CYTKのチャート


 CYTKの企業情報

symbol CYTK
会社名 Cytokinetics Inc (サイトキネティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症(ALS)の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。   サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する「Tirasemtiv(正式名称:CK-2017357)」の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。   Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
本社所在地 280 East Grand Avenue South San Francisco CA 94080 USA
代表者氏名 Leonard Patrick Gage レナード・パトリック・ゲージ
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-624-3000
設立年月日 35643
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 137人
url www.cytokinetics.com
nasdaq_url https://www.nasdaq.com/symbol/cytk
adr_tso
EBITDA EBITDA(百万ドル) -112.14400
終値(lastsale) 8.23
時価総額(marketcap) 449588415.31
時価総額 時価総額(百万ドル) 429.92230
売上高 売上高(百万ドル) 17.64500
企業価値(EV) 企業価値(EV)(百万ドル) 230.34630
当期純利益 当期純利益(百万ドル) -130.64600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense).

 CYTKのテクニカル分析


 CYTKのニュース

   Cytokinetics Incorporated : Corporate Presentation August 2020 | MarketScreener  2020/08/18 15:35:10 MarketScreener
35/94 … | August 18, 2020
   Cytokinetics Reports Second Quarter 2020 Financial Results  2020/08/06 20:00:00 GlobeNewswire
Top-line Results from GALACTIC-HF Expected in Q4 2020 Licensing Collaboration, Royalty Monetizations and Financing Provide Additional Capitalto Support…
   Cytokinetics Incorporated : Corporate Presentation July 2020 | MarketScreener  2020/07/21 23:51:03 MarketScreener
35/94 … | July 22, 2020
   Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2020/07/21 20:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the closing of its previously…
   Cytokinetics readies $150M stock offering (NASDAQ:CYTK)  2020/07/15 20:02:28 Seeking Alpha
Cytokinetics (NASDAQ:CYTK) initiates a $150M public offering of common stock. Price, volume and terms have yet to be announced.
   Cytokinetics Reports First Quarter 2020 Financial Results  2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
   Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool  2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
   The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering  2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
   Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release  2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cytokinetics Reports First Quarter 2020 Financial Results  2020/05/06 20:00:00 GlobeNewswire
Top-line Results for GALACTIC-HF Expected in Q4 2020 Ended Q1 with More Than Two Years of Going Forward Cash Based on 2020 Guidance SOUTH SAN…
   Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?  2020/04/29 16:34:24 Zacks Investment Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Cytokinetics Inc (CYTK) Q4 2019 Earnings Call Transcript | The Motley Fool  2020/03/04 05:00:29 The Motley Fool
CYTK earnings call for the period ending January 31, 2020.
   The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering  2020/02/14 13:23:03 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) AtriCure Inc. (NASDAQ: ATRC ) Beam Therapeutics Inc (NASDAQ: BEAM ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) ChemoCentryx Inc (NASDAQ: CCXI ) Cytokinetics, Inc. (NASDAQ: CYTK ) DexCom, Inc. (NASDAQ: DXCM ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fortress Biotech (NASDAQ: FBIO ) Insulet Corporation (NASDAQ: PODD ) Krystal Biotech Inc (NASDAQ: KRYS ) Masimo Corporation (NASDAQ: MASI ) NeoGenomics, Inc. (NASDAQ: NEO ) Nevro Corp (NYSE: NVRO ) Recro Pharma Inc (NASDAQ: REPH ) ResMed Inc. (NYSE: RMD ) Revolution Medicines Inc (NASDAQ: RVMD ) (went public Thursday) Syneos Health Inc (NASDAQ: SYNH ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) West Pharmaceutical Services Inc.
   Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Q4 Release  2020/02/13 17:31:32 Zacks Investment Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 サイトキネティクス CYTK Cytokinetics Incorporated)

 twitter  (公式ツイッターやCEOツイッターなど)